Results 231 to 240 of about 141,907 (307)
ABSTRACT The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laboratories in the 5‐year French nation‐wide multicenter prospective observational study.
Orianne Wagner‐Ballon +41 more
wiley +1 more source
Understanding Biologics in CRSwNP: Related Events and Insights. [PDF]
Izquierdo-Domínguez A +4 more
europepmc +1 more source
Sex-based differences in mumps immunity after a third dose of measles-mumps-rubella vaccine. [PDF]
Quach HQ +5 more
europepmc +1 more source
Wheat Allergy: Clinical Phenotypes, Diagnostic Approaches, and Management Strategies. [PDF]
Park JW, Park KH, Lee JH.
europepmc +1 more source
POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley +1 more source
ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel +13 more
wiley +1 more source
Multidimensional characterization of allergic rhinitis in Mysuru, South India: A cluster-based approach. [PDF]
Mahesh PA +11 more
europepmc +1 more source
Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion +15 more
wiley +1 more source

